In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the IRIS Registry, and all results were based on the study period from 01/01/2019 to 12/31/2019.
This was a retrospective cohort study of eyes in adult patients with a diagnosis of wet AMD who were treated with anti-VEGF agents from 01/01/2019 to 12/31/2019. IRIS Registry data from 01/01/2019 to 12/31/2019 for patients with a diagnosis of wet AMD who were treated with ≥1 anti-VEGF agent (excluding brolucizumab) were included. * Identification period: Patients fulfilling the selection criteria during the period from 01/01/2019 to 12/31/2019 were identified * Index date: 01/01/2019 * Study Period: 01/01/2019 to 12/31/2019 * Pre-index period: 01/01/2018 to 12/31/2018 * Post-index period: 01/01/2019 to 12/31/2019
Study Type
OBSERVATIONAL
Enrollment
331,541
intravitreal injection
intravitreal injection
intravitreal injection
Novartis Investigative Site
East Hanover, New Jersey, United States
Number of patients with Intraocular Inflammation (IOI) Adverse events (AEs) who were treated with anti-VEGF agents
Period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019 was assessed.
Time frame: earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019
Age
Age information was reported
Time frame: earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019
Gender information
Gender information was reported
Time frame: earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019
Number of patients at various Patient Region
Patient regions: Northeast, Midwest, South, West, Unknown
Time frame: earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019
Number of patients with Insurance type
Private, Medicare, Medicare Advantage, Medicaid, Other
Time frame: earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019
Number of patients with Laterality of wet Age-related macular degeneration (AMD)
Laterality of wet AMD: Unilateral, Bilateral
Time frame: Index date (defined as the date of first injection - 01/01/2019)
Number of patient eyes with the Provider specialty on date of first anti-VEGF injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The following types were included: Retina specialist, General ophthalmologist
Time frame: earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019
Number of patient eyes treated with anti-VEGF agent
The following types were included OD \[eye, right\], OS \[eye, left\], Unspecified
Time frame: Index date (defined as the date of first injection - 01/01/2019)
Number of anti-VEGF injections
Anti-VEGF utilization in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period was assessed. Measured at the patient level and patient-eye level.
Time frame: over a one-year period from 01/012019 to 31/12/2019
Number of patients with other ocular AEs in patients with wet AMD who were treated with anti-VEGF agents (excluding brolucizumab)
The following types were included: 1. Key ocular AEs 2. IOI events 3. RVO events 4. Unspecified RO 5. Autoimmune disorders (systemic lupus erythematosus \[SLE\], Behcet's disease, sarcoidosis, VKH disease, HLA-B27 syndromes, Drug hypersensitivity) 6. RV without RO (RAO and/or RVO)
Time frame: over a one-year period from 01/012019 to 31/12/2019